An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

Scripps News speaks with vaccine experts who say HHS funding cuts targeting mRNA vaccines could hinder other vaccine research ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

Federal funding cuts to mRNA technology research doesn't just impact COVID vaccines — experts say it could stall progress in treatment for cancers, rare disease and more.

IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late ...

The mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune ...

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

The "off-the-shelf" vaccine has also shown promising results for pancreatic cancer. Since the U.S. Preventive Services Task ...

The vaccine used in this trial, known as AHEAD-MERIT (BNT113-01), will help the immune system recognise and kill cancer cells ...

IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...

A one-size-fits-all vaccine has shown promising results in keeping hard-to-treat pancreatic cancers from coming back. The ...